- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01647594
Pilot Study for Young Women's Intervention (YWI Pilot)
Qualitative Assessment and Pilot Study for Young Women's Intervention
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Breast cancer in young women is a not a common disease, yet over 12,000 women under 40 are diagnosed with invasive breast cancer yearly in the United States alone and an additional 2,000 are diagnosed with noninvasive disease. Breast cancer is the leading cause of cancer-related deaths in women under 40, and survival rates for young women with breast cancer are lower than for their older counterparts. Further, in addition to being at higher risk of dying from breast cancer, despite often receiving more aggressive therapy, young women are at higher risk of distress both at diagnosis and in follow-up. Young women often have multiple roles and responsibilities that are harder to adjust to or get others to take on (e.g., parenting of young children, completing education, or building a career). Many young women are interested in having biologic children following treatment and are concerned about their future fertility. They also have an increased risk of harboring a genetic risk factor for breast cancer. Finally, in contrast to older women with breast cancer, who represent the majority of women with the disease, young women often feel isolated and lacking information, and they sometimes are concerned that their doctors are unsure of how to treat them. Distress may be confounded by lack of information on some of the risks they face, lack of provider awareness, information, and resources to address young women's concerns, and lack of peer support. These issues may contribute to the greater psychosocial distress seen in younger women at both diagnosis and in follow-up compared with older women. Thus, attention to these issues in younger women is warranted. Yet, research has revealed that needs of young women are not being met.
The primary goals of this study are to:
- conduct a qualitative assessment, through focus groups and key informant interviews, of concerns facing young women with breast cancer;
- evaluate materials developed to provide young women newly diagnosed with breast cancer information and resources regarding their unique concerns or physical activity through focus groups and a pilot study;
- conduct a pilot study of the Young Women's Intervention (YWI) as well as a Physical Activity Intervention (PAI) at 4 unique sites (3 will use the YWI and 2 will use the PAI- DFCI will pilot both interventions, one following the other) to evaluate the process for the intervention as well as to pilot surveys.
We aim to use the findings from the focus groups, key informant interviews and pilot study to inform the larger future Young Women's Intervention (YWI) study where the YWI arm will be compared to a Physical Activity Intervention (PAI). We plan to develop, implement and test a refined exportable and sustainable education and support intervention for young women with breast cancer and their oncology providers. First, we want to conduct focus groups and key informant interviews aiming to qualitatively assess the following domains: health/medical issues (i.e. side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues. In addition, the focus groups will be used to review the study materials and provide constructive feedback. In order to get a more diverse view of young women's concerns, we will conduct key informant interviews by telephone with young women with a history of breast cancer recruited from various regions of the country.
Information gained through the focus groups, key informant interviews and pilot of the intervention at four diverse practices will help us discover and resolve issues related to: administering the baseline survey, follow-up survey and provider survey; ensuring that the adapted intervention meets patient and provider needs, and evaluation the implementation process. When evaluating the patient surveys, investigators will assess issues that may have posed a barrier to patients' comprehension of study questions, such as the use of jargon or difficult vocabulary. In addition to piloting patient and provider surveys for material content, we will evaluate the intervention for feasibility of recruitment and implementation. We will refine materials and methods based on our pilot experience.
Collectively, results from the qualitative assessment and pilot will help finalize materials and surveys as well the methods of the study for a planned multi-site intervention study (YWI) funded by ASCO with support from Susan G. Komen for the Cure. A detailed plan of the parent study intervention will be submitted to the IRB upon completion of the focus groups, key informant interviews and pilot study described above.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maine
-
Brewer, Maine, United States, 04412
- Eastern Maine Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Lowell, Massachusetts, United States, 01854
- Lowell General Hospital
-
-
Texas
-
Houston, Texas, United States, 77024
- Texas Oncology Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to read and write English
- Age 18-42 at time of diagnosis
- Within 4 years of stage I-III invasive breast cancer diagnosis
- No known recurrence or metastatic disease
- Subject can be under active treatment at the time of study participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Young Women's Intervention (YWI)
|
The YWI consists of print and web-based materials.
Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources.
The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
|
|
Active Comparator: Physical Activity Intervention (PAI)
|
The PAI serves as the control group.
This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of intervention materials in addressing the unique issues facing young women with breast cancer
Time Frame: 1 year
|
Through focus groups and a pilot study, we will evaluate materials developed to provide young women newly diagnosed with breast cancer information and resources regarding their unique concerns or physical activity.
|
1 year
|
|
Evaluate process of intervention
Time Frame: 1 year
|
This pilot study is being conducted at 4 unique sites to assess the feasibility of recruitment and implementation, as well as to pilot the surveys.
|
1 year
|
|
Qualitative assessment of concerns facing young women with breast cancer
Time Frame: 1 year
|
The qualitative assessment will entail moderated in-person focus groups and key informant phone interviews, both of which will explore issues concerning young women with newly-diagnosed breast cancer.
The following domains will be assessed: health/medical issues (i.e.
side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of materials for helping providers improve cancer treatment for young women with breast cancer
Time Frame: Baseline, and about one week later
|
During the pilot intervention, we will pilot two patient surveys and one provider survey for material content and feedback on the intervention materials.
|
Baseline, and about one week later
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ann H. Partridge, M.D., M.P.H., Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-390
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on YWI
-
Dana-Farber Cancer InstituteAmerican Society of Clinical OncologyCompletedBreast CancerUnited States